ImmuneOnco Biopharmaceuticals (SEHK:1541) Losses Narrow 23.6% Annually Challenging Bearish Narratives

ImmuneOnco Biopharmaceuticals (Shanghai) (SEHK:1541) has laid out its FY 2025 scorecard with first half revenue of C¥44.0 million and a basic EPS loss of C¥0.37, alongside net income loss excluding extra items of C¥152.6 million. The company has reported revenue of C¥0.7 million in 1H 2024, C¥78.8 million in 2H 2024 and C¥44.0 million in 1H 2025. Over the same periods, basic EPS losses were C¥0.44, C¥0.39 and C¥0.37 respectively, providing a basis to assess how effectively revenue is being converted relative to ongoing losses. With a current share price of C¥4.46, the latest results focus attention on how margins develop from here.

See our full analysis for ImmuneOnco Biopharmaceuticals (Shanghai).

With the headline numbers on the table, the next step is to see how this earnings picture compares with the most widely held narratives around ImmuneOnco Biopharmaceuticals (Shanghai) and whether those views may warrant adjustment.

Curious how numbers become stories that shape markets? Explore Community Narratives

Five year loss reduction trend of 23.6% a year

• Over the past five years, earnings have moved from larger losses to smaller ones, with losses shrinking at an average rate of 23.6% a year according to the trailing data.
• What stands out for a bullish view is that this 23.6% annual reduction in losses sits alongside recent net income loss excluding extra items of C¥165.8 million in 1H 2024, C¥150.1 million in 2H 2024 and C¥152.6 million in 1H 2025, which:
  • Supports the bullish argument that the business is moving along a path of narrowing losses even though it is still unprofitable over the last 12 months with a C¥218.6 million loss on C¥154.3 million of revenue.
  • At the same time, reminds bulls that the journey is not linear, because the 1H 2025 loss of C¥152.6 million is slightly higher than 2H 2024, so progress is happening at the level of the multi year trend rather than every half year.

Trailing revenue of C¥154.3 million against continuing losses

• On a trailing twelve month view to 2H 2025, ImmuneOnco Biopharmaceuticals (Shanghai) booked C¥154.3 million of revenue and recorded a net income loss excluding extra items of C¥218.6 million, with a trailing basic EPS loss of C¥0.53.
• Bears point to this profile of C¥218.6 million in losses on C¥154.3 million of revenue as evidence that the business model still needs to absorb high costs, and the numbers offer some support for that concern:
  • Across the last three reported half year periods, net income loss excluding extra items stayed in a relatively tight band between C¥150.1 million and C¥165.8 million, which critics highlight as a sign that losses are still large in absolute terms even as EPS moves from a C¥0.44 loss in 1H 2024 to a C¥0.37 loss in 1H 2025.
  • However, the same data that shows repeated losses also records the 23.6% annual reduction in losses over five years, so the bearish focus on current burn needs to be weighed against that longer run improvement in profitability.

On that backdrop, it helps to see how other investors are joining the dots between shrinking losses and the current valuation in the community view for this stock, so you can test your own thinking against a wider range of narratives before making any decisions.📊 Read the what the Community is saying about ImmuneOnco Biopharmaceuticals (Shanghai).

P/S of 11x sits between peers and sector

• Based on the latest trailing figures, the stock trades on a P/S of 11x compared with a peer average of 6.7x and a broader Hong Kong Biotechs industry average of 13.1x, while the share price is C¥4.46.
• Critics highlight this 11x P/S multiple as a key bearish point, arguing the stock is priced at a premium to closer peers despite being unprofitable, and the reported data gives some context to that view:
  • The company remains loss making on a trailing basis with C¥218.6 million of net income loss excluding extra items, so the current P/S is being supported by revenue of C¥154.3 million rather than by positive earnings.
  • On the other hand, the fact that the 11x P/S sits below the sector’s 13.1x average means investors are not paying the highest multiples in the Hong Kong biotech space, which softens the most pessimistic version of the bearish valuation argument.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on ImmuneOnco Biopharmaceuticals (Shanghai)'s growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With both risks and rewards in play, does the overall tone feel too cautious or too optimistic? Act while the details are fresh in mind and compare the company’s profile against the 1 key reward and 1 important warning sign

See What Else Is Out There

ImmuneOnco Biopharmaceuticals (Shanghai) is still posting sizeable losses on C¥154.3 million of trailing revenue, with an 11x P/S and no profit support yet.

If you want ideas where the balance between risk, profitability and valuation looks more comfortable today, compare this profile against the 284 resilient stocks with low risk scores and see which companies feel like a better fit for your capital right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com